The latest updates highlight three strong mid-stage results in the pharma pipeline, as Eli Lilly, Merck, and AbbVie advance promising therapies toward Phase 3 trials.
Pharma pricing faces tighter scrutiny this month as courts, state regulators and global agreements target drug, device and hospital supply-chain markups.
Wegovy pill users switching from injectable GLP-1 drugs lost 4.1 percent of their body weight in three months, highlighting a potential new pathway for treatment continuity.
Biodeal's 135 million-unit acquisition of Biological E’s sterile injectable facility highlights India’s intensifying CDMO capacity scramble.
Digital health is becoming central to BRICS healthcare as AI, telemedicine and interoperable health records expand access, especially across India's rural and remote regions.
India's healthcare capacity is expanding as Global Health invests Rs 165.82 crore in land for a 350-plus-bed Medanta hospital in Ghaziabad, adding to the country's organised healthcare infrastructure.
India is positioned to gain as the US zeroes tariffs on key specialty drugs, creating new opportunities for Indian pharma manufacturers.
Lilly and Novo intensify the weight loss and diabetes market battle with new efficacy, oral drug, and cardiovascular data.
Akums gets DCGI approval for 0.5 mg Colchicine tablets, marking a first-time-in-India milestone in preventive cardiology and cardiovascular care.
Apixaban oral suspension is Lupin's latest formulation development, receiving tentative US FDA approval for its 1.25 mg/mL product as an alternative to tablets.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
